Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,180 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07090954 | A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 32 | Genrix (Shanghai) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06580223 | Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma | not yet recruiting | Phase 3 | 530 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER |
| 1 |
| Jul 18, 2025 |
| clinicaltrials |
| NCT07070934 | CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?(ASCTvsCAR-T) | not yet recruiting | Phase 2 | 60 | Xuzhou Medical UniversityOTHER | 0 | Jul 17, 2025 | clinicaltrials |
| NCT07070960 | A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible(CAR-T) | not yet recruiting | N/A | 35 | Xuzhou Medical UniversityOTHER | 0 | Jul 17, 2025 | clinicaltrials |
| NCT07068906 | A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 | 27 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07055724 | Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis | not yet recruiting | Phase 2 | 17 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 0 | Jul 9, 2025 | clinicaltrials |
| NCT07034755 | Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma | not yet recruiting | N/A | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06720207 | Efficacy of 68Ga-Pentixafor PET/MR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions | not yet recruiting | — | 30 | Shanghai East HospitalOTHER | 0 | Jun 27, 2025 | clinicaltrials |
| NCT07032324 | A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )(CT1190B) | not yet recruiting | Phase 1 | 27 | Qian WenbinOTHER | 1 | Jun 23, 2025 | clinicaltrials |
| NCT07031700 | A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL | not yet recruiting | Phase 2 | 22 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jun 22, 2025 | clinicaltrials |
| NCT07024147 | JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07018271 | A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma Patients | not yet recruiting | N/A | 24 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Jun 12, 2025 | clinicaltrials |
| NCT07015021 | The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients(DKPD) | not yet recruiting | N/A | 72 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Jun 11, 2025 | clinicaltrials |
| NCT07012980 | Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL | not yet recruiting | Phase 2 | 38 | Shanghai Zhongshan HospitalOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT07008053 | BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma | not yet recruiting | Phase 2 | 37 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06963866 | Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT(ASCTvsCAR-T) | not yet recruiting | Phase 2 | 60 | Xuzhou Medical UniversityOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT06961500 | Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A(PROOF) | not yet recruiting | Phase 2 | 133 | Sun Yat-sen UniversityOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06942507 | Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia(BRZ-WM) | not yet recruiting | N/A | 104 | Peking Union Medical College HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06931704 | Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)(IFM 2024_06) | not yet recruiting | Phase 2 | 176 | Nantes University HospitalOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06918015 | Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma | not yet recruiting | Phase 2 | 58 | Zhejiang Cancer HospitalOTHER | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06925958 | A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Histological Expression of 68Ga-NOTA-SCH001 in Patients With Multiple Myeloma | not yet recruiting | N/A | 15 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Apr 13, 2025 | clinicaltrials |
| NCT06921044 | A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL | not yet recruiting | Phase 2 | 33 | Xiaohui HeOTHER | 0 | Apr 10, 2025 | clinicaltrials |
| NCT06750965 | Multi-center Screening for Serum M Protein | not yet recruiting | — | 10,000 | Zhujiang HospitalOTHER | 0 | Apr 9, 2025 | clinicaltrials |
| NCT06913179 | CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma(CAR-T-allo) | not yet recruiting | Phase 1 | 30 | Xuzhou Medical UniversityOTHER | 0 | Apr 6, 2025 | clinicaltrials |
| NCT06913192 | Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma(AUTO-CAR-T) | not yet recruiting | Phase 1 | 50 | Xuzhou Medical UniversityOTHER | 0 | Apr 6, 2025 | clinicaltrials |
| NCT06880601 | Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma(TALIM) | not yet recruiting | Phase 2 | 52 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Apr 3, 2025 | clinicaltrials |
| NCT06895512 | A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma | not yet recruiting | Phase 3 | 386 | Shanghai Henlius BiotechINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06894693 | A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies | not yet recruiting | Phase 1 | 13 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 0 | Mar 25, 2025 | clinicaltrials |
| NCT06888752 | LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma | not yet recruiting | N/A | 35 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06888856 | Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients(MMOMICS) | not yet recruiting | — | 200 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06825845 | Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy | not yet recruiting | — | 1,500 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 0 | Feb 13, 2025 | clinicaltrials |
| NCT05944783 | Bioequivalence Studies of Dasatinib 100 Mg(BE-Dasatinib) | not yet recruiting | Phase 4 | 46 | Centro de Atencion e Investigacion MedicaNETWORK | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06817759 | Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer | not yet recruiting | N/A | 60 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06799676 | A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 42 | Fuling ZhouOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06787807 | Proteomic Analysis of Patients Undergoing Bariatric Surgery | not yet recruiting | N/A | 103 | Universidade Federal de PernambucoOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06757894 | Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma | not yet recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06748521 | Dynamic CtDNA-guided Targeted Therapy in DLBCL | not yet recruiting | Phase 2 | 108 | Ruijin HospitalOTHER | 0 | Dec 27, 2024 | clinicaltrials |
| NCT06750991 | CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) | not yet recruiting | Phase 2 | 34 | Ruijin HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06744894 | SIL as Maintenance Therapy in Multiple Myeloma | not yet recruiting | Phase 2 | 50 | Navy General Hospital, BeijingOTHER | 0 | Dec 20, 2024 | clinicaltrials |
| NCT06742138 | To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma | not yet recruiting | Phase 3 | 284 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Dec 19, 2024 | clinicaltrials |
| NCT06734624 | The Microbiome in Blood Cancer and HLH | not yet recruiting | — | 750 | University of NottinghamOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06721598 | An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders | not yet recruiting | — | 60 | National Research Center for Hematology, RussiaNETWORK | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06705725 | Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma | not yet recruiting | Phase 1 | 38 | Carbiogene Therapeutics Co. Ltd.INDUSTRY | 0 | Nov 26, 2024 | clinicaltrials |
| NCT06656221 | A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 29 | Ruijin HospitalOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT06646666 | ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT | not yet recruiting | Phase 2 | 35 | Ruijin HospitalOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06667583 | 5p15/ 9q22/ 15q22 Hyperdiploidy and Their Significance in Multiple Myeloma Patients | not yet recruiting | — | 40 | Assiut UniversityOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06669143 | Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission | not yet recruiting | Phase 2 | 19 | Ruijin HospitalOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06659770 | A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma | not yet recruiting | — | 200 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 0 | Oct 26, 2024 | clinicaltrials |
| NCT06655519 | An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | not yet recruiting | Phase 1 | 12 | Peking University People's HospitalOTHER | 0 | Oct 23, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 29, 2025source: clinicaltrials